Experienced Pharmaceutical Marketing Executive to Lead Initiatives in New
And Existing Markets for ENBREL
SEATTLE, June 20 /PRNewswire/ -- Promoting ENBREL(R) (etanercept) for its
newest indications is among the first opportunities for Immunex's new vice
president of marketing for ENBREL, Barry Labinger. Immunex Corporation
(Nasdaq: IMNX) announced the new addition to the marketing team at the company
today. With ENBREL being studied in numerous diseases, Labinger will also
drive planning for marketing initiatives for potential new indications for the
drug.
"ENBREL is experiencing strong sales growth, and generating interest by
clinical researchers in a number of potential new indications," said
Mark Booth, general manager, ENBREL. "The marketing talent and expertise that
Barry brings to the table will help continue the momentum the Immunex and
Wyeth Ayerst team have built behind the ENBREL brand."
Labinger has ten years marketing and sales experience in the
pharmaceutical industry. Most recently, Labinger was the Senior Director of
marketing for the U.S. Diabetes Franchise at Bristol-Myers Squibb. Labinger
holds a Bachelors degree with an Economics major from Northwestern University,
as well as an MBA from the Kellogg School of Management at Northwestern
University.
Immunex Corporation and Wyeth-Ayerst Laboratories, division of American
Home Products Corporation (NYSE: AHP), market ENBREL in North America. Other
American Home Products Corporation affiliates will market ENBREL outside of
North America. Immunex manufactures ENBREL. Additional information about
ENBREL, including full prescribing information, can be found on the company-
sponsored website at (http://www.enbrel.com) or by calling toll-free 888-4ENBREL
(888-436-2735).
Immunex Corporation is a biopharmaceutical company dedicated to improving
lives through immune system science innovations.
American Home Products Corporation's Wyeth-Ayerst division is a major
research-oriented pharmaceutical company with leading products in the areas of
women's health care, cardiovascular disease therapies, central nervous system
drugs, anti-inflammatory agents, vaccines and generic pharmaceuticals.
AHP owns a majority interest in Immunex. AHP is one of the world's
largest research-based pharmaceutical and health care products companies. It
is a leader in the discovery, development, manufacturing and marketing of
prescription drugs, including biotechnological and vaccine products, animal
health care products and over-the-counter medications.
NOTE: This release contains forward-looking statements that involve risks
and uncertainties, including risks associated with clinical development,
regulatory approvals, patent litigation, product commercialization and other
risks described from time to time in the SEC reports filed by Immunex,
including the most recently filed 10-K and 10-Q forms. For more information,
please refer to http://www.immunex.com.
SOURCE Immunex Corporation
 back to top
Related links:
http://www.immunex.com
Company News On-Call:
http://www.prnewswire.com/comp/434644.html or fax,
800-758-5804, ext. 434644
CONTACT:
media, Tim Warner, 206-470-4193, or
investors, Mark Leahy, 206-389-4363, both of Immunex Corporation
|
